The role of complement-mediated inflammation in miscarriage and preterm birth

Costantini, K. J., Coulthard, L. G., Woodruff, T. M., Taylor, S. M. and Callaway, L. K. (2010). The role of complement-mediated inflammation in miscarriage and preterm birth. In: Berhane Ghebrehiwet, Ellinor I. Peerschke and Richard R. Kew, Molecular Immunology. Proceedings of: XXIII International Complement Workshop. XXIII International Complement Workshop, New York, NY, U.S.A., (2272-2273). 1-5 August 2010. doi:10.1016/j.molimm.2010.05.222


Author Costantini, K. J.
Coulthard, L. G.
Woodruff, T. M.
Taylor, S. M.
Callaway, L. K.
Title of paper The role of complement-mediated inflammation in miscarriage and preterm birth
Conference name XXIII International Complement Workshop
Conference location New York, NY, U.S.A.
Conference dates 1-5 August 2010
Proceedings title Molecular Immunology. Proceedings of: XXIII International Complement Workshop   Check publisher's open access policy
Journal name Molecular Immunology   Check publisher's open access policy
Place of Publication Oxford, U.K.
Publisher Pergamon Press
Publication Year 2010
Year available 2011
Sub-type Oral presentation
DOI 10.1016/j.molimm.2010.05.222
ISSN 0161-5890
1872-9142
Editor Berhane Ghebrehiwet
Ellinor I. Peerschke
Richard R. Kew
Volume 47
Issue 13
Start page 2272
End page 2273
Total pages 2
Language eng
Formatted Abstract/Summary
Miscarriage and preterm birth are leading causes of perinatal morbidity and mortality. There is therefore a pressing need for research into the aetiology of these conditions, with an aim to develop novel therapeutics.

In the first set of experiments, pregnant mice were administered a single dose of lipopolysaccharide (LPS) at gestational day (GD) 9.5 or GD15.5. Expression of complement in human placenta was also studied. Placentas from growth restricted neonates exhibited significant placental deposition of C3 compared to healthy controls. A clinical study is currently underway to further elucidate this.

Together, these results suggest a key pathogenic role for C5a in pregnancy and strongly support the investigation of pharmacological agents that block C5a activation, such as the potent C5aR antagonist PMX53, as a potential therapeutic for women susceptible to LBWs and recurrent miscarriages.
Subjects 1107 Immunology
Q-Index Code EX
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Presented during the oral session "Animal Models of Disease - II" as Abstract #44.

Document type: Conference Paper
Collections: Non HERDC
School of Biomedical Sciences Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 15 Aug 2010, 00:02:29 EST